Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H48BrN6O9S.Na |
| Molecular Weight | 891.803 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC=C2C(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](NC(=O)OC4CCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C([O-])=O)=CC(=NC2=C1Br)C6=CSC(NC(=O)C(C)C)=N6
InChI
InChIKey=JYIOGGWFNHGWMN-CWNXUBRBSA-M
InChI=1S/C40H49BrN6O9S.Na/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41;/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48);/q;+1/p-1/t21-,23-,27+,32-,40-;/m1./s1
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor developed by Boehringer-Ingelheim for the treatment of hepatitis C. Faldaprevir in combination with pegylated interferon and ribavirin, or interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin provides high sustained virological response rates for HCV genotype 1 infection. The most common adverse events were gastrointestinal disorders, rash, and photosensitivity. The interferon-free combination of faldaprevir and deleobuvir with ribavirin was effective for HCV genotype 1 infection, although further improvements will still be needed. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AB-20
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
DBSALT002080
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
56594927
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
C166460
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
DTXSID60153309
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL1241348
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
100000155568
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
1494Q15E7Z
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
1215856-44-2
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY | |||
|
SUB129617
Created by
admin on Mon Mar 31 18:27:31 GMT 2025 , Edited by admin on Mon Mar 31 18:27:31 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD